Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial
In brief
Dirozalkib more than doubled progression-free survival versus crizotinib in ALK-positive lung cancer
In a randomized phase III trial of 275 patients with advanced ALK-positive lung cancer who had not received an ALK inhibitor, median time without progression was 29.5 months with dirozalkib versus 12.9 months with crizotinib. Severe side effects and treatment discontinuations were less frequent with dirozalkib, but whether it improves overall survival remains unknown.
- Journal
- Cancer communications (London, England) (Q1)
- Published
- 10 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Ying Liu, Xiangjiao Meng, Yan Yu, Jianhua Chen, Runxiang Yang, Laiyu Liu, et al.
- PMID
- 43011476
- DOI
- 10.34133/cancomm.0068
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (top studies of the week, 15 November 2026): Randomized phase III trial of targeted therapy for advanced lung
Abstract
Background: Dirozalkib is a highly selective anaplastic lymphoma kinase (ALK) inhibitor with intracranial antitumor activity against crizotinib-resistant mutations. This phase III trial evaluated dirozalkib versus crizotinib in patients with ALK inhibitor-naïve, ALK-positive, advanced non-small-cell lung cancer (NSCLC). Methods: In this multicenter, randomized, open-label DIAMOND-2 trial, adult patients with ALK inhibitor-naïve, ALK-positive, advanced NSCLC who either had received no prior systemic therapy or had experienced disease progression or intolerance after one prior chemotherapy regimen were randomly assigned 1:1 to dirozalkib (500 mg once daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival (PFS). Results: Between 2022 January 24 and 2023 April 30, 275 patients were randomly assigned to receive dirozalkib (n = 137) or crizotinib (n = 138). As of 2025 May 31, the median follow-up durations were 32.8 and 31.6 months, respectively. Median investigator-assessed PFS was 29.5 (95% confidence interval [CI] = 20.3 to not reached) months with dirozalkib versus 12.9 (95% CI = 11.1 to 17.6) months with crizotinib (hazard ratio [HR] = 0.47, 95% CI = 0.34 to 0.66; P < 0.001). Blinded-independent-central-review-assessed PFS was also significantly prolonged with dirozalkib (median PFS, 27.5 versus 12.9 months; HR = 0.54, 95% CI = 0.39 to 0.74; P < 0.001). Grade ≥3 treatment-emergent adverse events (TEAEs) were less frequent with dirozalkib than with crizotinib (60.6% versus 72.5%), and TEAEs led to treatment discontinuation in 2.2% and 7.2% of patients, respectively. Conclusions: Dirozalkib significantly improved PFS versus crizotinib, with a manageable safety profile, supporting its use as a first-line therapy for ALK-positive advanced NSCLC. Trial registration: This trial was registered at ClinicalTrials.gov on 2022 January 24 (NCT05204628).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.